Trial Evaluating Epanova for MACE Risk Reduction Discontinued
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
All articles by Steve Duffy
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
Rilonacept Gets Breakthrough Therapy Status for Recurrent Pericarditis
The FDA has granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis.
Vericiguat Reduces Risk for Heart Failure Hospitalization, CV Death in HFrEF
Vericiguat (Merck and Bayer) reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure, according to new phase 3 data.
FDA Fast-Tracks Therapy for Patients at Risk for AKI After CABG
The FDA has granted Fast Track designation to ASP1128, an investigational treatment for patients at increased risk of developing moderate to severe AKI after CABG and/or valve surgery.
Oral Suspension Formulation of Amlodipine Now Available
Katerzia (amlodipine) Oral Suspension, 1mg/mL is now commercially available.
Next post in Pediatric Cardiology
